LivaNova PLC
LIVN
株式のランク
#3835
LivaNova PLC is a global medical technology company dedicated to developing,... LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
株価
$78.25
最終同期: 2026-10-21
時価総額
$4.30B
変化（1日）
-1.84%
変化（1年）
42.65%
国
GB
取引 LivaNova PLC (LIVN)
カテゴリー
Healthcare
LivaNova PLC（LIVN）の収益
Jun 2026 時点の収益 TTM: $1.47B
LivaNova PLC の最新の財務報告によると、現在の収益 (TTM) は $1.47B です。2023 年には $1.15B の収益があり、これは 2022 年の $1.02B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
LivaNova PLC の収益履歴（2000 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.47B | 17.40% |
| 2024 | $1.25B | 8.66% |
| 2023 | $1.15B | 12.89% |
| 2022 | $1.02B | -1.31% |
| 2021 | $1.04B | 10.82% |
| 2020 | $934.24M | -13.83% |
| 2019 | $1.08B | -2.06% |
| 2018 | $1.11B | 9.35% |
| 2017 | $1.01B | -16.61% |
| 2016 | $1.21B | 316.35% |
| 2015 | $291.56M | 3.38% |
| 2014 | $282.01M | 10.89% |
| 2013 | $254.32M | 16.39% |
| 2012 | $218.50M | 14.72% |
| 2011 | $190.46M | 13.52% |
| 2010 | $167.78M | 16.83% |
| 2009 | $143.60M | 18.45% |
| 2008 | $121.23M | -7.44% |
| 2007 | $130.97M | 6.10% |
| 2006 | $123.44M | 19.33% |
| 2005 | $103.44M | -6.57% |
| 2004 | $110.72M | 5.99% |
| 2003 | $104.47M | 49.00% |
| 2002 | $70.11M | 46.40% |
| 2000 | $47.89M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $46.59B | 3,065.79% |
US
|
|
| $35.48B | 2,311.40% |
IE
|
|
| $25.84B | 1,655.81% |
US
|
|
| $21.00B | 1,326.83% |
US
|
|
| - | - |
DE
|
